Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent…
Biotechnology
US, Boston [HQ]
RYTM/Financial Reporting
Income Statements
Profit & Loss · 11 Statements · From 2023 to 2012Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2012 | 2013 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | - - | - - | - - | 3.00 | 23.00 | 77.00 | |
|
EPS
|
-0.36 | -0.43 | -0.66 | -1.55 | -2.54 | -2.39 | -3.70 | -2.96 | -1.37 | -3.51 | -3.20 | |
| Diluted in mil. | -0.36 | -0.43 | -0.66 | -1.55 | -2.54 | -2.39 | -3.70 | -2.96 | -1.37 | -3.51 | -3.20 | |
|
Profit
|
- - | - - | - - | - - | - - | - - | - - | - - | 2.00 | 21.00 | 68.00 | |
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | - - | 81.01 | 90.98 | 87.99 | |
| Pre Tax | -18.00 | -21.00 | -11.00 | -25.00 | -33.00 | -74.00 | -140.00 | -133.00 | -69.00 | -181.00 | -184.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | -2,207.10 | -766.22 | -237.79 | |
| ETR | - - | - - | - - | - - | -3.19 | -5.88 | 4.34 | 2.44 | 2.31 | -1.08 | -0.31 | |
| Net | -18.00 | -21.00 | -11.00 | -25.00 | -33.00 | -74.00 | -134.00 | -130.00 | -68.00 | -183.00 | -184.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | -2,156.21 | -774.52 | -238.52 | |
| EBITDA | -18.00 | -21.00 | -10.00 | -25.00 | -30.00 | -78.00 | -146.00 | -136.00 | -170.00 | -175.00 | -168.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | - - | - - | - - | -5,391.85 | -744.22 | -217.58 | |
| Operating Income | -18.00 | -21.00 | -10.00 | -25.00 | -32.00 | -78.00 | -146.00 | -136.00 | -170.00 | -179.00 | -184.00 | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | - - | -5,391.85 | -757.92 | -238.10 | |
| Interest Income | - - | - - | - - | - - | - - | 4.00 | 5.00 | 2.00 | - - | 4.00 | 13.00 | |
| Loss | -18.00 | -21.00 | -10.00 | -25.00 | -32.00 | -78.00 | -146.00 | -136.00 | -173.00 | -202.00 | -261.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | -2.00 | -9.00 | |
|
Operating Expenses
|
-18.00 | -21.00 | -10.00 | -25.00 | -32.00 | -78.00 | -146.00 | -136.00 | -172.00 | -200.00 | -252.00 | |
| R&D | -15.00 | -18.00 | -7.00 | -19.00 | -22.00 | -50.00 | -109.00 | -90.00 | -104.00 | -108.00 | -134.00 | |
| G&A | -2.00 | -3.00 | -3.00 | -6.00 | -9.00 | -28.00 | - - | - - | - - | - - | - - | |
| SG&A | -2.00 | -3.00 | -3.00 | -6.00 | -9.00 | -28.00 | -36.00 | -46.00 | -68.00 | -92.00 | -117.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -1.00 | -1.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | - - | - - | -5.00 | -13.00 | |
| Other Expenses | - - | - - | - - | - - | -1.00 | -4.00 | -5.00 | -2.00 | -100.00 | -1.00 | - - | |
|
WA Shares Outstanding
|
50.00 | 50.00 | 16.00 | 16.00 | 13.00 | 31.00 | 36.00 | 44.00 | 49.00 | 52.00 | 57.00 | |
| Diluted | 50.00 | 50.00 | 16.00 | 16.00 | 13.00 | 31.00 | 36.00 | 44.00 | 49.00 | 52.00 | 57.00 |